Top

World Journal of Urology

Published in:

01-12-2015 | Original Article

The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome

Authors: Xiangyu Zhang, Xiaofang Zeng, Lini Dong, Xiaokun Zhao, Xiaobing Qu

Published in: World Journal of Urology | Issue 12/2015

Abstract

Purpose

To evaluate the effects of simvastatin and atorvastatin in elderly male patients with benign prostatic hyperplasia (BPH) accompanied by metabolic syndrome (MetS).

Methods

Eligible patients aged >60 year with BPH accompanied by MetS were randomly assigned to receive 40 mg of simvastatin daily, 20 mg of atorvastatin daily or placebo (control group) treatment for 12 months. Serum lipids, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), prostate-specific antigen, prostate volume (PV) and the International Prostate Symptom Score (IPSS) were tested before and after treatment.

Results

The levels of serum total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol, hs-CRP, IL-6 and IPSS was decreased, serum high-density lipoprotein cholesterol (HDL-C) was increased, and PV was reduced in the patients following treatments with statins. The PV of the patients who received simvastatin were reduced more than those of the patients who received atorvastatin. The decrease in PV was more significant in the obesity patients than in the normal weight patients and in the hyperlipidemia patients than in the normal-lipid patients following the statin interventions. The reduction in PV was positively related to the decreases in the levels of TC and IL-6 and to the increase in the level of HDL-C.

Conclusions

Simvastatin and atorvastatin significantly reduced PV, improved lower urinary tract symptoms, and slowed the clinical progression of BPH possibly by lowering cholesterol and anti-inflammatory factors.

Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359CrossRefPubMed

Pashootan P, Ploussard G, Cocaul A, De Gouvello A, Desgrandchamps F(2014) Association between metabolic syndrome and severity of lower urinary tract symptoms: an observational study in a 4,666 European men cohort. BJU Int 17. doi: 10.1111/bju.12931. [Epub ahead of print]

Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH (2013) The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 82(3):674–679CrossRefPubMed

Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X (2014) Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 93(2):214–219CrossRefPubMed

Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101–106CrossRefPubMed

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P et al (2007) Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177(4):1395–1400CrossRefPubMed

Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 29(3):310–316CrossRef

Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101(3):313–318CrossRefPubMedPubMedCentral

Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780CrossRefPubMedPubMedCentral

10.

Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA (2005) Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 62(1):27–33CrossRefPubMed

11.

Zhang X, Shen F, Dong L, Zhao X, Qu X (2013) Influence and pathophysiological mechanisms of simvastatin on prostatic hyperplasia in spontaneously hypertensive rats. Urol Int 91(4):467–473CrossRefPubMed

12.

Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19(4):113–121CrossRefPubMed

13.

Ozden C, Ozdal OL, Urgancioglu G et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–206CrossRefPubMed

14.

Hammarsten J, Hogstedt B (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39(2):151–158CrossRefPubMed

15.

Mitropoulos D, Ploumidou K, Kyroudi-Voulgari A et al (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl 2(1):20CrossRef

16.

Vikram A, Jena GB, Ramarao P (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyper-insulinemia with benign prostate hyperplasia. Prostate 70(1):79–89CrossRefPubMed

17.

Vignozzi L, Gacci M, Cellai I et al (2013) Fat boosts, while androgen receptor activation counteracts BPH-associated prostate inflammation. Prostate 73(8):789–800CrossRefPubMed

18.

St Sauver JL, Jacobsen SJ, Jacobson DJ et al (2011) Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 107(3):443–450CrossRefPubMedPubMedCentral

19.

Marino G, Pugno E, Cevoli R, Griffa D, Pastorini S, Cocimano V (1991) Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 43(4):279–282PubMed

20.

Hamilton RJ, Goldberg KC, Platz EA et al (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100(21):1511–1518CrossRefPubMed

21.

Hall SA, Chiu GR, Link CL et al (2011) Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol 21(3):149–155CrossRefPubMedPubMedCentral

22.

Stamatiou KN, Zaglavira P, Skolarikos A et al (2008) The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 34(5):555–561CrossRefPubMed

23.

Mills IW, Crossland A, Patel A et al (2007) Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 52(2):503–509CrossRefPubMed

24.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM (2010) Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 171(5):571–582CrossRefPubMedPubMedCentral

25.

Pace G, Di Massimo C, De Amicis D, Vicentini C, Ciancarelli MG (2011) Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol 37(5):617–622CrossRefPubMed

26.

Rodríguez-Berriguete G, Prieto A, Fraile B et al (2010) Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 21(4):241–250PubMed

27.

Fibbi B, Penna G, Morelli A et al (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475–488CrossRefPubMed

28.

Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni-Berthold I (2013) Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J Suppl 47(1):20–27CrossRefPubMed

Title: The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome
Authors: Xiangyu Zhang
Xiaofang Zeng
Lini Dong
Xiaokun Zhao
Xiaobing Qu
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-015-1550-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2015

Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma

Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians

Impact of 2004 ISUP/WHO classification on bladder cancer grading

Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta

Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study